Identification of the role of MED6 in the development and prognosis of lung adenocarcinoma based on multi-omics profiling.

IF 3.3 3区 医学 Q2 ONCOLOGY
Journal of Cancer Pub Date : 2025-04-13 eCollection Date: 2025-01-01 DOI:10.7150/jca.110981
Changqing Yang, Ding Cheng, Shuo Wang, Baichuan Wang, Yingxi Li, Guixin Wang, Xingkai Wang, Cangchang Shi, Yao Tian, Keyun Zhu, Jing Feng
{"title":"Identification of the role of MED6 in the development and prognosis of lung adenocarcinoma based on multi-omics profiling.","authors":"Changqing Yang, Ding Cheng, Shuo Wang, Baichuan Wang, Yingxi Li, Guixin Wang, Xingkai Wang, Cangchang Shi, Yao Tian, Keyun Zhu, Jing Feng","doi":"10.7150/jca.110981","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Recent studies have highlighted the importance of Mediator complex subunits in cancer, but their specific roles in LUAD are still unclear. <b>Methods:</b> The CRISPR-Cas9 loss-of-function data was used to assess gene dependency in cell growth. RNA-seq data were analyzed to evaluate the prognostic value of Mediator subunits and explore their downstream pathways. Single-cell sequencing data were utilized to examine the tumor microenvironment in LUAD. A drug sensitivity analysis was performed to identify potential therapeutic options. <b>Results:</b> Mediator complex subunit 6 (MED6) was found to influence tumor cell growth in LUAD. Additionally, MED6 expression levels were associated with patient prognosis. MED6-positive tumor cells showed more active interactions with other cells in the LUAD microenvironment, promoting tumor progression. Based on MED6 expression, drugs such as paclitaxel, afatinib, and brivanib were identified as potential treatments. <b>Conclusions:</b> This study revealed the role of MED6 in LUAD and its potential as a biomarker. Our findings suggest that MED6 has an effect on LUAD progression and provide valuable insights for patient stratification and personalized treatment strategies.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 7","pages":"2362-2374"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036094/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.110981","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Recent studies have highlighted the importance of Mediator complex subunits in cancer, but their specific roles in LUAD are still unclear. Methods: The CRISPR-Cas9 loss-of-function data was used to assess gene dependency in cell growth. RNA-seq data were analyzed to evaluate the prognostic value of Mediator subunits and explore their downstream pathways. Single-cell sequencing data were utilized to examine the tumor microenvironment in LUAD. A drug sensitivity analysis was performed to identify potential therapeutic options. Results: Mediator complex subunit 6 (MED6) was found to influence tumor cell growth in LUAD. Additionally, MED6 expression levels were associated with patient prognosis. MED6-positive tumor cells showed more active interactions with other cells in the LUAD microenvironment, promoting tumor progression. Based on MED6 expression, drugs such as paclitaxel, afatinib, and brivanib were identified as potential treatments. Conclusions: This study revealed the role of MED6 in LUAD and its potential as a biomarker. Our findings suggest that MED6 has an effect on LUAD progression and provide valuable insights for patient stratification and personalized treatment strategies.

基于多组学分析鉴定MED6在肺腺癌发展和预后中的作用
背景:肺腺癌(LUAD)是最常见的肺癌亚型。最近的研究强调了中介复合物亚基在癌症中的重要性,但它们在LUAD中的具体作用仍不清楚。方法:使用CRISPR-Cas9功能缺失数据评估细胞生长中的基因依赖性。分析RNA-seq数据以评估Mediator亚基的预后价值并探索其下游通路。利用单细胞测序数据检测LUAD的肿瘤微环境。进行药物敏感性分析以确定潜在的治疗方案。结果:发现中介复合物亚单位6 (MED6)影响LUAD的肿瘤细胞生长。此外,MED6表达水平与患者预后相关。med6阳性的肿瘤细胞在LUAD微环境中与其他细胞表现出更积极的相互作用,促进肿瘤进展。基于MED6的表达,紫杉醇、阿法替尼、布里伐尼等药物被确定为潜在的治疗药物。结论:本研究揭示了MED6在LUAD中的作用及其作为生物标志物的潜力。我们的研究结果表明,MED6对LUAD的进展有影响,并为患者分层和个性化治疗策略提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信